PTX-200 and Carboplatin in Ovarian Cancer

NCT01690468 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment stopped prior to Phase 1b, change in strategic focus

Conditions

Ovarian Cancer

Interventions

DRUG: Triciribine
DRUG: Carboplatin

Sponsor

Prescient Therapeutics, Ltd.